A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 21, 2016

Primary Completion Date

February 22, 2024

Study Completion Date

February 22, 2024

Conditions

MelanomaMerkel Cell CarcinomaOther Solid Tumors

Interventions

DRUG

TALIMOGENE LAHERPAREPVEC (TVEC)

RADIATION

Hypofractionated Radiotherapy

Trial Locations (3)

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Westchester, Harrison

Memorial Sloan Kettering Monmouth, Middletown